Physician profile
Christina M Huddleston
NPI 1598110462
$25,559.06
in general payments reported to CMS, 2019-2025
35 companies · $21K in 2025
The $21K reported for 2025 was more than what 92% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $24.69 · 2021: $269 · 2022: $1,213 · 2023: $1,022 · 2024: $1,734 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $4,848 · Travel and Lodging: $686 · Education: $295 · Consulting Fee: $50.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,450.00 |
| Food and Beverage | $4,848.40 |
| Travel and Lodging | $685.80 |
| Education | $294.60 |
| Consulting Fee | $50.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $19,417.64 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Genzyme Corporation | $1,230.59 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $915.35 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $644.88 | 2021-2025 | Hyqvia, Takhzyro, Cuvitru |
| Glaxosmithkline, LLC. | $622.68 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $322.32 | 2022-2025 | Xolair |
| Grifols USA, LLC | $265.03 | 2021-2025 | Xembify, Gamunex-C |
| Novartis Pharmaceuticals Corporation | $254.93 | 2022-2025 | |
| Amgen INC. | $206.69 | 2022-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $198.94 | 2023-2024 | |
| Biocryst US Sales Co., LLC | $193.89 | 2021-2025 | Orladeyo |
| Csl Behring | $175.34 | 2020-2025 | Hizentra, Privigen, Haegarda |
| Leo Pharma INC. | $146.97 | 2025 | Adbry |
| Octapharma USA, INC. | $116.97 | 2022-2024 | Cutaquig, Octagam Immune Globulin (Human), Panzyga |
| Optinose US, INC. | $114.87 | 2021-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $66.59 | 2025 | Alvesco |
| Pfizer INC. | $64.61 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $60.89 | 2021-2022 | |
| Covis Pharma Gmbh | $56.66 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $56.14 | 2025 | Neffy |
| Blueprint Medicines Corporation | $55.92 | 2023-2024 | Ayvakit |
| Abbvie INC. | $53.54 | 2022-2023 | |
| Adma Biomanufacturing LLC | $50.75 | 2024 | |
| Organon LLC | $36.54 | 2025 | |
| Lilly USA, LLC | $26.06 | 2025 | Ebglyss |
| Greer Laboratories, INC. | $25.85 | 2024 | Palforzia |
| Arcutis Biotherapeutics, INC. | $23.40 | 2025 | Zoryve |
| Pharming Healthcare, INC. | $23.18 | 2023 | Ruconest |
| Insmed, INC. | $22.11 | 2025 | Arikayce |
| Kaleo, INC. | $21.24 | 2024 | Auvi-Q |
| Phadia US INC. | $19.69 | 2024 | Immunocap |
| Hospira, INC. | $18.55 | 2024 | |
| Gc Biopharma USA, INC. | $17.63 | 2025 | Alyglo |
| Ionis Pharmaceuticals, INC. | $17.05 | 2025 | Dawnzera |
| Aimmune Therapeutics, INC. | $15.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Huddleston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.